Windlas Biotech Limited (NSEI: WINDLAS)
Health Care · Life Sciences Tools & Services · IN
Rs993.60
+4.65% today · -0.6% 1Y
Windlas Biotech Limited (NSEI: WINDLAS) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $214.30M and employs 1,385 people.
Over the last twelve months the share price has lost 0.6%, trading between 697.40 and 1.05K.
Tweenvest scores Windlas Biotech Limited across four factors: quality 69/100, value 35/100, growth 67/100, dividend 50/100. Its strongest factor is quality.
WINDLAS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $214.30M
- Revenue (TTM)
- $99.64M
- P/E
- 31.92
- EPS
- 31.13
- Dividend yield
- 0.63%
- Beta (5Y)
- 0.27
- 52-week high
- Rs1,045.45
- 52-week low
- Rs697.40
- Avg volume (3M)
- —
- Shares outstanding
- 20.64M
- Employees
- 1,385
- Next earnings
- —
About Windlas Biotech Limited
Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale commercial production of various generic pharmaceutical and nutraceutical items. Through these services, it assists clients in bringing both established and innovative pharmaceutical and nutraceutical products to market, which are then sold under the clients' proprietary brand names. Beyond its CDMO segment, Windlas Biotech also develops and manufactures its own portfolio of domestic trade generics and over-the-counter (OTC) brands, catering to the nutritional, ayurvedic, wellness, and personal care sectors. These in-house products reach consumers via a dual distribution approach: traditional offline channels like distributors, stockists, retail pharmacies, and institutional tenders, alongside a robust online presence through various e-commerce platforms. The company's international reach extends through exports, primarily to markets such as Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. Established in 2001, Windlas Biotech is headquartered in Gurugram, India.
- ISIN
- INE0H5O01029
- Founded
- 2001
- Listed since
- Aug 16, 2021
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.47B | $628.74 | -0.08% |
| Danaher CorporationNYSE: DHR | $151.22B | $215.11 | -1.71% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $69.06B | CN¥155.84 | -4.31% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.21B | CHF592.00 | +0.71% |
| Agilent Technologies, Inc.NYSE: A | $43.33B | $153.43 | -3.50% |
| IQVIA Holdings Inc.NYSE: IQV | $42.84B | $260.24 | +0.16% |
| Waters CorporationNYSE: WAT | $40.36B | $410.75 | +0.01% |
Figures last refreshed Aug 18, 2026.